Pharnext Executes a Financing Agreement with Néovacs for EUR 20.7 million Net to Further Develop PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Following this financing program, carried out through the issuance of simple obligations in several tranches for a total nominal amount of approximately EUR 21 million (i.e., approximately EUR 20.7 million net) with share warrants attached, Néovacs …